癌症治疗相关葡萄膜炎的局部治疗:病例系列及文献综述
本文为回顾性病例系列及文献综述,纳入5例免疫治疗或靶向治疗继发葡萄膜炎的患者,采用局部治疗并按葡萄膜炎亚型管理。前葡萄膜炎单独使用1%醋酸泼尼松龙滴眼液成功治疗,后节受累者使用二氟泼尼松龙滴眼液、玻璃体腔注射曲安奈德或联合治疗成功。作者据此提出局部治疗路径:先局部激素,难治性全葡萄膜炎或后葡萄膜炎加用注射激素。
要点
- 5例癌症治疗相关葡萄膜炎患者中,前葡萄膜炎单用1%醋酸泼尼松龙滴眼液即成功治疗。
- 后节受累且对1%醋酸泼尼松龙滴眼液难治者,经二氟泼尼松龙滴眼液、玻璃体腔注射曲安奈德或联合治疗成功。
- 孤立性前葡萄膜炎无需维持局部治疗,后葡萄膜炎和全葡萄膜炎需长期低剂量局部治疗。
核心结论
- 作者基于本系列及现有文献,提出癌症治疗相关葡萄膜炎的局部治疗路径:先局部激素,难治性全葡萄膜炎或后葡萄膜炎时加用注射激素。
研究设计与样本
- 该研究为经机构审查委员会批准的回顾性病例系列,纳入免疫治疗或靶向治疗继发葡萄膜炎并接受局部治疗的患者,并进行了聚焦文献综述。
主要发现
- 共纳入5例患者,中位年龄54岁(范围31至75岁),葡萄膜炎在癌症治疗开始后3至12个月发病。
- 所有患者均接受检查点抑制剂治疗,其中1例还接受了靶向治疗;2例表现为前葡萄膜炎,2例为全葡萄膜炎,1例为后葡萄膜炎。
- 5例患者中4例在多模态影像上显示后节炎症证据。
- 前葡萄膜炎经单独1%醋酸泼尼松龙滴眼液成功治疗,对1%醋酸泼尼松龙滴眼液难治的后节受累经二氟泼尼松龙滴眼液、玻璃体腔注射曲安奈德或联合治疗成功。
- 孤立性前葡萄膜炎患者无需维持局部治疗,后葡萄膜炎和全葡萄膜炎患者需要长期低剂量局部治疗。
临床怎么用
- 作者提出,癌症治疗相关葡萄膜炎的局部治疗可从局部激素开始,难治性全葡萄膜炎或后葡萄膜炎时加用注射激素。
- 后节影像上的亚临床炎症对二氟泼尼松龙滴眼液或玻璃体腔注射激素治疗反应良好。
- 后节受累患者可能需要更积极的管理和长期维持治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Immunotherapy and targeted therapy for metastatic cancer may cause immune-related adverse events (irAEs) such as uveitis. If irAEs are severe or require systemic steroids, cancer therapy is often held or discontinued. Local steroid therapy for cancer therapy-associated uveitis allows the continuation of cancer therapy. This series demonstrates successful management of cancer therapy-associated uveitis with local therapy based on uveitis subtype. METHODS: This is an Institutional Review Board-approved retrospective case series of patients with uveitis secondary to immunotherapy or targeted therapy managed with local treatment, and focused literature review. RESULTS: Five patients (median age: 54, range 31 to 75) were included. Time to uveitis onset following cancer therapy initiation was 3 to 12 months. All patients received checkpoint inhibitor therapy; one patient additionally received targeted therapy. Two patients presented with anterior uveitis, two with panuveitis and one with posterior uveitis. Four of five patients demonstrated evidence of posterior segment inflammation on multimodal imaging. Anterior uveitis was successfully treated with topical prednisolone acetate 1% (PA 1%) alone, and posterior segment involvement recalcitrant to topical PA 1% was treated successfully with topical difluprednate, intravitreal triamcinolone acetonide or a combination. Patients with isolated anterior uveitis did not require maintenance topical therapy; those with posterior and panuveitis required chronic low-dose topical therapy. CONCLUSION: Based on our series as well as the existing literature demonstrating the use of local therapy for irAEs, we propose an approach to local therapy for cancer therapy-associated uveitis starting with topical steroids and initiating injectable steroids in cases of recalcitrant panuveitis or posterior uveitis. Subclinical inflammation on posterior segment imaging responds robustly to difluprednate or intravitreal steroid therapy, and patients with posterior segment involvement may require more aggressive management and long-term maintenance.
引用
- Venkat AG, Arepalli S, Sharma S, et al. Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. Br J Ophthalmol. 2019. PMID: 31409649. doi:10.1136/bjophthalmol-2019-314403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。